MAMDC4

Summary

MAMDC4 (MAM domain containing 4, HGNC:24083) is a protein-coding gene on chromosome 9q34.3, encoding Apical endosomal glycoprotein (Q6UXC1). Probably involved in the sorting and selective transport of receptors and ligands across polarized epithelia.

Predicted to enable protein histidine phosphatase activity. Predicted to be involved in peptidyl-histidine dephosphorylation. Predicted to be located in cytosol.

Source: NCBI Gene 158056 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 292 total
• MANE Select transcript: NM_206920

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24083
Approved symbol	MAMDC4
Name	MAM domain containing 4
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	AEGP, DKFZp434M1411, EDTB
Ensembl gene	ENSG00000177943
Ensembl biotype	protein_coding
OMIM	617208
Entrez	158056

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 11 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000317446, ENST00000445819, ENST00000479475, ENST00000481327, ENST00000485732, ENST00000905522, ENST00000905523, ENST00000905524, ENST00000905525, ENST00000905526, ENST00000905527, ENST00000905528, ENST00000905529, ENST00000914727

RefSeq mRNA: 1 — MANE Select: NM_206920 NM_206920

CCDS: CCDS7010

Canonical transcript exons

ENST00000317446 — 27 exons

Exon	Start	End
ENSE00001402053	136854762	136854850
ENSE00001409308	136853777	136853907
ENSE00001420716	136856710	136856826
ENSE00001425358	136858186	136858276
ENSE00001600860	136853102	136853209
ENSE00001660942	136853545	136853670
ENSE00001671593	136853285	136853458
ENSE00003471015	136859005	136859132
ENSE00003491271	136859886	136860064
ENSE00003496238	136854937	136855110
ENSE00003504969	136854539	136854676
ENSE00003545307	136856907	136857041
ENSE00003557050	136857165	136857298
ENSE00003557540	136858400	136858546
ENSE00003560836	136853992	136854076
ENSE00003561553	136854211	136854336
ENSE00003561704	136856018	136856149
ENSE00003564659	136857979	136858097
ENSE00003594069	136859209	136859317
ENSE00003606670	136855732	136855848
ENSE00003642204	136855254	136855338
ENSE00003643481	136855431	136855619
ENSE00003647471	136858719	136858853
ENSE00003662169	136857367	136857586
ENSE00003677367	136857659	136857796
ENSE00003843588	136852346	136852462
ENSE00003844690	136860562	136860799

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 96.84.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.5619 / max 490.1639, expressed in 24 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
99578	0.3562	11
99579	0.1503	10
99575	0.0293	15
99576	0.0197	13
99577	0.0064	5

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	96.84	gold quality
cerebellar hemisphere	UBERON:0002245	96.01	gold quality
cerebellar cortex	UBERON:0002129	95.87	gold quality
cerebellum	UBERON:0002037	94.68	gold quality
mucosa of transverse colon	UBERON:0004991	93.17	gold quality
apex of heart	UBERON:0002098	91.84	gold quality
pituitary gland	UBERON:0000007	91.52	gold quality
adenohypophysis	UBERON:0002196	91.34	gold quality
right lobe of liver	UBERON:0001114	89.46	gold quality
right lobe of thyroid gland	UBERON:0001119	89.32	gold quality
right uterine tube	UBERON:0001302	88.40	gold quality
left lobe of thyroid gland	UBERON:0001120	87.43	gold quality
spleen	UBERON:0002106	86.90	gold quality
transverse colon	UBERON:0001157	86.52	gold quality
thyroid gland	UBERON:0002046	85.98	gold quality
sural nerve	UBERON:0015488	85.59	gold quality
ileal mucosa	UBERON:0000331	84.51	gold quality
jejunal mucosa	UBERON:0000399	84.18	gold quality
liver	UBERON:0002107	84.15	gold quality
heart left ventricle	UBERON:0002084	84.13	gold quality
body of pancreas	UBERON:0001150	84.10	gold quality
lower esophagus mucosa	UBERON:0035834	83.77	gold quality
cardiac ventricle	UBERON:0002082	83.56	gold quality
right testis	UBERON:0004534	83.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.86	gold quality
small intestine	UBERON:0002108	81.51	gold quality
left testis	UBERON:0004533	81.45	gold quality
right adrenal gland cortex	UBERON:0035827	81.04	gold quality
endocervix	UBERON:0000458	81.02	gold quality
body of stomach	UBERON:0001161	80.68	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

4 targeting MAMDC4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4640-5P	97.42	66.33	1543
HSA-MIR-4726-5P	97.24	65.67	1299
HSA-MIR-744-5P	93.78	65.29	230
HSA-MIR-10396A-5P	93.49	65.54	172

Literature-anchored findings (GeneRIF, showing 4)

• Results suggest that it is the presence of rare syntenic SEC16A and MAMDC4 deletions that increases susceptibility to axial spondyloarthritis in family members who carry the HLA-B*27 allele. (PMID:25956157)
• Expression is localized to the apical surface of the neonatal enterocyte and decreases over time in association with bacterial colonization of the intestine (PMID:27821716)
• Regulation of YAP and Wnt signaling by the endosomal protein MAMDC4. (PMID:38787854)
• PMID:7829488 describes studies in rat, however, the human MAMDC4 gene product appears to be a homolog of rat apical early endosomal glycoprotein. (PMID:7829488)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
danio_rerio	mamdc2b	ENSDARG00000073695
mus_musculus	Mamdc4	ENSMUSG00000026941

Paralogs (4): MDGA1 (ENSG00000112139), MDGA2 (ENSG00000139915), MAMDC2 (ENSG00000165072), MALRD1 (ENSG00000204740)

Protein

Protein identifiers

Apical endosomal glycoprotein — Q6UXC1 (reviewed: Q6UXC1)

Alternative names: MAM domain-containing protein 4

All UniProt accessions (2): Q6UXC1, A0A0C4DGF7

UniProt curated annotations — full annotation on UniProt →

Function. Probably involved in the sorting and selective transport of receptors and ligands across polarized epithelia.

Subcellular location. Membrane.

Miscellaneous. Gene prediction based on similarity to rat ortholog. May be due to intron retention.

Isoforms (3)

UniProt ID	Names	Canonical?
Q6UXC1-1	1	yes
Q6UXC1-2	2
Q6UXC1-3	3

RefSeq proteins (1): NP_996803* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000998	MAM_dom	Domain
IPR002172	LDrepeatLR_classA_rpt	Repeat
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR023415	LDLR_class-A_CS	Conserved_site
IPR036055	LDL_receptor-like_sf	Homologous_superfamily
IPR051560	MAM_domain-containing	Family

Pfam: PF00057, PF00629

UniProt features (35 total): domain 9, glycosylation site 6, disulfide bond 6, splice variant 3, sequence variant 3, region of interest 2, topological domain 2, signal peptide 1, chain 1, compositionally biased region 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UXC1-F1	79.91	0.30

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (6): 229–241, 236–254, 248–265, 457–468, 464–481, 475–490

Glycosylation sites (6): 203, 281, 339, 583, 636, 835

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 44 (showing top): ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GATA1_04, WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_8D, SRC_UP.V1_UP, chr9q34, SUPT16H_TARGET_GENES, GSE8685_IL15_ACT_IL2_STARVED_VS_IL21_ACT_IL2_STARVED_CD4_TCELL_DN, JINESH_BLEBBISHIELD_VS_LIVE_CONTROL_UP, MANNE_COVID19_COMBINED_COHORT_VS_HEALTHY_DONOR_PLATELETS_UP, ZHONG_PFC_C3_ASTROCYTE, GAO_SMALL_INTESTINE_24W_C4_ENTEROCYTE_PROGENITOR_SUBTYPE_2, GAO_LARGE_INTESTINE_24W_C10_ENTEROCYTE, GSE12003_MIR223_KO_VS_WT_BM_PROGENITOR_8D_CULTURE_DN, DESCARTES_FETAL_INTESTINE_INTESTINAL_EPITHELIAL_CELLS, DESCARTES_FETAL_STOMACH_MUC13_DMBT1_POSITIVE_CELLS

GO Biological Process (2): nervous system development (GO:0007399), protein transport (GO:0015031)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
system development	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

726 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MAMDC4	CCDC183	Q5T5S1	575
MAMDC4	LCN12	Q6JVE5	552
MAMDC4	TMEM141	Q96I45	549
MAMDC4	NPDC1	Q9NQX5	483
MAMDC4	VWCE	Q96DN2	460
MAMDC4	ANKDD1B	A6NHY2	448
MAMDC4	ETDA	Q3ZM63	447
MAMDC4	ABCA2	Q9BZC7	443
MAMDC4	TMEM121	Q9BTD3	440
MAMDC4	OR10G2	Q8NGC3	397
MAMDC4	TMEM252	Q8N6L7	394
MAMDC4	ENTPD2	Q9Y5L3	387
MAMDC4	TCEANC2	Q96MN5	376
MAMDC4	USP54	Q70EL1	359
MAMDC4	MS4A13	Q5J8X5	348

IntAct

3 interactions, top by confidence:

A	B	Type	Score
MAMDC4		psi-mi:“MI:0914”(association)	0.350
MAMDC4		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (18): MAMDC4 (Synthetic Lethality), SUPT7L (Affinity Capture-MS), TTC28 (Affinity Capture-MS), CENPN (Affinity Capture-MS), TADA1 (Affinity Capture-MS), TAF6L (Affinity Capture-MS), ANGEL2 (Affinity Capture-MS), C3orf33 (Affinity Capture-MS), SLC30A9 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), ADCY6 (Affinity Capture-MS), AHCTF1 (Affinity Capture-MS), ATP8B2 (Affinity Capture-MS), ASPHD2 (Affinity Capture-MS), POM121C (Affinity Capture-MS)

ESM2 similar proteins: A0EQL2, A2AJ76, A2AJA7, A6H8M9, A8T650, A8T682, A8T688, A8T6A6, D3ZLH5, F1QVU0, O08628, O75173, O88839, P04278, P08514, P08689, P0DV84, P15196, P20701, P29376, P32970, P38570, P60882, P80012, P97497, P97793, Q13444, Q15113, Q5RFQ8, Q5TM20, Q61398, Q63191, Q6UXC1, Q7Z304, Q7Z442, Q7Z7M0, Q8BNJ2, Q8CG85, Q8K1S7, Q8NBP7

Diamond homologs: A2AJA7, O14786, P28824, P85171, P98072, P98073, P98157, Q0PMG2, Q0WYX8, Q63191, Q6UXC1, Q8NFP4, Q8QFX6, Q9QWJ9, A0A182C2Z2, A2RUV9, B3EWZ5, B3EWZ6, B8V7S0, B8VIV4, F1RWC3, O08628, O08859, O15537, O18806, O35276, O35375, O35474, O43854, O43897, O57382, O57460, O60462, O60494, O70244, O88783, P00451, P12259, P12263, P13497

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

292 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	246
Likely benign	20
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3824 predictions. Top by Δscore:

Variant	Effect	Δscore
9:136854077:G:GG	donor_gain	1.0000
9:136854675:GG:G	donor_gain	1.0000
9:136854676:GG:G	donor_gain	1.0000
9:136855110:GGTA:G	donor_loss	1.0000
9:136855112:T:G	donor_loss	1.0000
9:136857973:T:A	acceptor_gain	1.0000
9:136857976:CAG:C	acceptor_loss	1.0000
9:136857977:A:AG	acceptor_gain	1.0000
9:136857977:AGG:A	acceptor_loss	1.0000
9:136857978:G:GG	acceptor_gain	1.0000
9:136857978:G:GT	acceptor_loss	1.0000
9:136857978:GGC:G	acceptor_gain	1.0000
9:136858093:GGAGG:G	donor_gain	1.0000
9:136858094:GAGG:G	donor_gain	1.0000
9:136858094:GAGGG:G	donor_gain	1.0000
9:136858096:GG:G	donor_gain	1.0000
9:136858097:GG:G	donor_gain	1.0000
9:136858098:G:GG	donor_gain	1.0000
9:136858098:GTG:G	donor_loss	1.0000
9:136858255:G:GT	donor_gain	1.0000
9:136859205:TCA:T	acceptor_loss	1.0000
9:136859207:A:AG	acceptor_gain	1.0000
9:136859207:AGA:A	acceptor_loss	1.0000
9:136859208:G:GG	acceptor_gain	1.0000
9:136859208:GATC:G	acceptor_gain	1.0000
9:136852459:CTGGG:C	donor_loss	0.9900
9:136852461:GG:G	donor_gain	0.9900
9:136852462:GG:G	donor_gain	0.9900
9:136852463:G:GG	donor_gain	0.9900
9:136852464:T:A	donor_loss	0.9900

AlphaMissense

7302 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:136857244:G:C	W763C	0.993
9:136857244:G:T	W763C	0.993
9:136855769:G:C	W503C	0.991
9:136855769:G:T	W503C	0.991
9:136855799:G:C	W513C	0.991
9:136855799:G:T	W513C	0.991
9:136858055:G:C	W926C	0.991
9:136858055:G:T	W926C	0.991
9:136854812:A:C	S329R	0.988
9:136854814:C:A	S329R	0.988
9:136854814:C:G	S329R	0.988
9:136859090:G:C	W1093C	0.988
9:136859090:G:T	W1093C	0.988
9:136858473:G:C	W995C	0.987
9:136858473:G:T	W995C	0.987
9:136853862:G:C	W180C	0.984
9:136853862:G:T	W180C	0.984
9:136857012:T:C	F727S	0.984
9:136855105:T:C	F398L	0.983
9:136855107:C:A	F398L	0.983
9:136855107:C:G	F398L	0.983
9:136855797:T:A	W513R	0.983
9:136855797:T:C	W513R	0.983
9:136857513:G:C	W830C	0.983
9:136857513:G:T	W830C	0.983
9:136858471:T:A	W995R	0.982
9:136858471:T:C	W995R	0.982
9:136859127:T:C	F1106L	0.982
9:136859129:C:A	F1106L	0.982
9:136859129:C:G	F1106L	0.982

dbSNP variants (sampled 300 via entrez): RS1000582189 (9:136856604 T>C), RS1001219862 (9:136852946 G>A), RS1001545789 (9:136860552 C>T), RS1001698063 (9:136860436 G>A,C), RS1001731571 (9:136852753 T>C,G), RS1002999074 (9:136851900 G>A), RS1003079988 (9:136858087 G>A,T), RS1003152782 (9:136855245 T>C), RS1003307279 (9:136859753 A>G), RS1003401494 (9:136852040 C>A,T), RS1004031281 (9:136859917 T>A,C), RS1004083675 (9:136859770 T>C), RS1004460121 (9:136851858 G>A), RS1004726665 (9:136852939 G>A), RS1004825169 (9:136852674 T>C)

Disease associations

OMIM: gene MIM:617208 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	decreases methylation	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
abrine	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Air Pollutants	affects expression, increases abundance	1
Diethylhexyl Phthalate	decreases expression	1
Doxorubicin	decreases expression	1
Methapyrilene	decreases methylation	1
Ozone	affects expression, increases abundance	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety